ClinicalTrials.gg
Not yet recruitingNCT07292519Updated Dec 18, 2025

Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)

A Phase 2 interventional study of Tirzepatide and Take Control CBT Module in Alcohol Use Disorder (AUD), Overweight or Obese and Comorbidities and Coexisting Conditions, sponsored by South West Sydney Local Health District. Not yet recruiting at 1 site in Australia. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by South West Sydney Local Health District · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Alcoholism with a site in Australia — 5 open to participants now, 5 under way, none of them phase 3. Alcoholism · Australia.

Planned enrollment
11th of 16
46 · median 83
Started
2026
the only one that year
Phase 2
5 of 17
2 open now
Registered
17th of 17
by date
Lead sponsor
8 of 17
South West Sydney Local Health District

Among the 17 studies in Alcoholism with a site in Australia, this one is the 11th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 2, and was the 17th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

5 of the 17 studies in Alcoholism with a site in Australia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alcoholism with a site in Australia, or all of them as a file.
02

Study summary

The investigators approach is to conduct a Phase II Double-Blind randomised controlled trial with individuals with co-occurring Alcohol Use Disorder and overweight/obesity (AUD-OOB) to receive either a sub-cutaneous injection of Tirzepatide (2.5 mg for 4 weeks followed by 5 mg for 4 weeks) or visually matched sham saline injection, in combination with a structured behavioural intervention (Take Control CBT Module). The primary aim of the study is evaluate the efficacy of the intervention on the number of heavy drinking days (defined as 5+ standard drinks for men, 4+ standard drinks for women) during the final month of treatment (weeks 5 to 8) compared to baseline. The secondary aim of the study is to assess treatment effects on alcohol related (e.g. number drinks consumed per day, abstinent days) and cardio-metabolic outcomes (e.g. body weight in kg, waist circumference, blood pressure, HbA1c, total cholesterol etc...), and summarise safety outcomes associated with use (e.g. frequency and severity of side effects, number of serious adverse events, treatment related discontinuations). The study will also include neurobiological assessments such as functional magnetic resonance imaging (fMRI) and lab-based psychophysiology to assess the impact of tirzepatide on change in brain activity and autonomic responses to alcohol and food cues.

Read the detailed description

Individuals with co-occurring AUD and overweight or obesity (AUD-OOB) are an underserved population with high relapse rates and elevated cardiometabolic risk. Recent evidence suggests that Tirzepatide can simultaneously reduce alcohol intake in animal models and craving, drinks per day and heaving drinking days over a 9-week period in non-treatment seeking individuals with AUD. Tirzepatide's dual incretin mechanism offers the potential to simultaneously reduce alcohol use and improve metabolic health in this group, with a favourable safety profile and weekly dosing that supports adherence. As rates of AUD and obesity continue to rise, identifying pharmacological strategies that can address both conditions concurrently is a high public health priority.

This is a phase II, randomised, double-blind, placebo-controlled clinical trial of 46 individuals designed to evaluate the effects of Tirzepatide on alcohol consumption, craving and cardiometabolic outcomes in adults with alcohol used disorder and overweight/obesity (AUD-OOB), to receive either a sub-cutaneous injection of tirzepatide (n=23) or a visually matched placebo (n=23).

The trial will be conducted at a single clinical site in New South Wales, Australia. The Edith Collins Centre (ECC) will serve as the coordinating centre.

In summary participants will:

  • Be randomized in a double-blind fashion to receive either tirzepatide or a visually matched placebo
  • Receive subcutaneous injections of tirzepatide (2.5mg for 4 weeks followed by 5mg for 4 weeks) or a matching placebo over an eight-week treatment period.
  • Visit the clinic weekly (for 8 weeks) for medication administration, clinical monitoring and brief behavioural support (delivered by the "Take Control" computerised CBT program).
  • Receive clinical assessments including alcohol use, cardiometabolic biomarkers (HbA1c, lipids, ASCVD) and alcohol biomarkers (PEth) at baseline (week 0), end of treatment (week 9) and follow-up (week 12).
  • Undergo neuroimaging (fMRI) and psychophysiology assessmenrts as a substudy at 2 timepoints: baseline (week 0) and between week 7-9. These tasks will assess neural and autonomic reactivity to alcohol and food-related cues, and will support a mechanistic understanding of tirzepatide's impact on reward sensitivity and stress responsivity-key predictors of relapse and treatment outcome

The primary aim of this clinical trial is to examine the effects of weekly tirzepatide (2.5 mg for 4 weeks followed by 5 mg for 4 weeks) versus placebo injections, in combination with a structured behavioural intervention (Take Control) on alcohol consumption in adults with alcohol use disorder and overweight/obesity (AUD-OOB). The main question[s] it aims to answer are:

  1. Main outcome: To determine the efficacy of Tirzepatide on alcohol related outcomes, the change in the number of heavy drinking days during the final four weeks of treatment (week 5 - 8, with a final assessment at week 9) will be assessed by comparison with baseline (28 days prior to baseline visit). Researchers will compare tirzepatide to placebo injections (a look-alike substance that contains no drug) to see if weekly tirzepatide administration can reduce the number of heavy drinking days.
  2. Secondary Outcomes:

    i) To evaluate changes in additional alcohol-related outcomes:

    • Number of drinks per drinking day measured using the Timeline Follow Back
    • Number of abstinent days measured using the Timeline Follow Back
    • WHO drinking risk level
    • Weekly alcohol craving
    • Proportion of participants with zero heavy drinking days (Weeks 5-8)

    ii) To evaluate changes in cardiometabolic indices from baseline to Week 9:

    • Body weight
    • Waist circumference
    • Blood pressure
    • HbA1c
    • Total cholesterol
    • Triglycerides
    • 10-year ASCVD risk score

    iii) To assess safety outcomes associated the delivery of Tirzepatide, investigators will measure the:

    • Frequency and severity of side effects (graded using CTCAE V5.0 and monitored continuously throughout the intervention).
    • Number of serious adverse events (SAEs)
    • Treatment-related discontinuation

    Participants will complete additional neurobiological assessments including functional magnetic resonance imaging (fMRI) and laboratory-based psychophysiology at two timepoints: baseline (pre-treatment) and the final treatment visit (Week 8), which coincides with the final tirzepatide/placebo dose and final Take Control session. These measures will assess changes in brain activity and autonomic responses to alcohol and food cues.

03

Conditions studied

  • Alcohol Use Disorder (AUD)
  • Overweight or Obese
  • Comorbidities and Coexisting Conditions

Keywords

  • Alcohol Use Disorder (AUD)
  • Overweight or Obese
  • Concurrent Treatment of AUD and overweight/obesity
  • Tirzepatide
  • Phase II Double-blind RCT
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 21 to 75 years
  2. Meet criteria for alcohol use disorder (AUD) with at least moderate severity (≥4 symptoms in the past year)
  3. Have an average daily alcohol consumption of:

    • ≥60g ethanol/day for men
    • ≥40g ethanol/day for women (based on the 28 days prior to the baseline visit)
  4. (BMI) ≥27 kg/m²
  5. Currently motivated to reduce or stop drinking but not engaged in formal AUD treatment
  6. Able and willing to attend weekly clinic visits and complete all study procedures
  7. Fluent in English and able to provide
  8. Stable housing situation (not transient or homeless)

Exclusion criteria

Exclusion Criteria:

  1. Past-year diagnosis of another substance use disorder (except nicotine or mild cannabis use disorder)
  2. Recent (past 30 days) self-reported illicit drug use (excluding cannabis), or a positive urine drug screen for non-cannabis substances
  3. History of significant alcohol withdrawal, defined by:

    • History of seizure, delirium tremens, or
    • Hospitalisation for withdrawal, or
    • CIWA-Ar score >9, or
    • PAWS score >4 at screening
  4. Currently engaged in pharmacological or behavioral treatment for AUD, or prior engagement within the past 3 months
  5. History or current diagnosis of:

    • Type 1 or Type 2 diabetes
    • Diabetic complications (e.g. retinopathy)
    • ≥6.5% at screening
  6. Significant psychiatric illness, including:

    • Current active suicidal ideation (per C-SSRS)
    • Lifetime history of psychosis or bipolar disorder
    • Unstable depression or anxiety interfering with daily functioning
  7. Chronic or acute pancreatitis
  8. Significant liver disease or abnormal liver function tests (, AST, ALP, >3× )
  9. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) type I/II
  10. Estimated (eGFR) \<30 mL/min
  11. Recent significant weight loss (>5% of body weight in past 30 days)
  12. Use of any weight loss medication (e.g., orlistat, bupropion-naltrexone) or AUD medication (e.g., naltrexone, acamprosate, topiramate, varenicline) in the past 3 months
  13. Use of tirzepatide or any GLP-1 receptor agonist in the past 6 months
  14. Pregnant or breastfeeding, or not using effective (females of )
  15. Inability to attend weekly visits due to work/travel/schedule conflicts
  16. Participation in another clinical trial involving an product
  17. Shared household with a current or past participant in this trial
  18. Scheduled for surgery requiring anaesthesia within 90 days of enrolment that would interfere with participation or follow-up
  19. History of muscle wasting, bone disorders (e.g. sarcopenia)
  20. Active gastrointestinal conditions that could interfere with treatment (e.g., severe GERD)
  21. Uncontrolled hypertension, recent heart attack or stroke (within 6 months)

    Extra Exclusion criteria for Those Participants Agreeing to Participate in Neuroimaging \& Psychophysiology Tasks:

  22. Presence of any MRI-incompatible metal implants or devices, including pacemakers, aneurysm clips, insulin pumps, or cochlear implants
  23. History of brain surgery or penetrating head trauma
  24. Prior occupation as a machinist, welder, or metal worker (due to risk of metal fragments)
  25. Non-removable piercings or dental hardware that would interfere with MRI
  26. History of claustrophobia likely to interfere with scanning compliance aa. Neurological disorders (e.g., epilepsy, multiple sclerosis) likely to confound neuroimaging data bb. Inability to lie still or tolerate MRI procedures cc. Patient weighting over 159kg (MRI scan limit) dd. Any other condition or medication judged by the investigator to preclude safe participation
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Tirzepatide: subcutaneous administration of Tirzepatide plus CBT ("Take Control" program)

    1 x Screening, Baseline Clinical Assessments, Neuroimaging (T0) and Psychophysiology, Randomisation (Visit 1, Week 0) From Dose 1 (Visit 2, week 1) to Dose 4 (Visit 5, week 4), with "Take Control" CBT module: 2.5mg Tirzepatide dose administration, and a 15-20 minutes computer-based CBT module. From Dose 5 (Visit 6 , week 5) to Dose 8 (Visit 9, week 8) with "Take Control" CBT module: 5.0mg dose administration (unless contraindicated by study physician), and a 15-20 minutes computer-based CBT module. Neuroimaging substudy (Visit 10, week 8): After the final medication and CBT module, participants complete final neuroimaging timepoint (T1). End-of-treatment (Visit 11, week 9 \& Visit 12, week 12): One and four weeks after the last dose and neuroimaging, participants will complete psychophysiology assessments using the same tasks as baseline.

    Drug: Tirzepatide · Behavioral: Take Control CBT Module

  • Placebo comparator
    Placebo: subcutaneous administration of placebo plus CBT ("Take Control" program)

    1 x Screening, Baseline Clinical Assessments, Neuroimaging (T0) and Psychophysiology, Randomisation (Visit 1, Week 0) From Dose 1 (Visit 2, week 1) to Dose 4 (Visit 5, week 4), with "Take Control" CBT module: matched placebo dose administration OR matched placebo, and a 15-20 minutes computer-based CBT module. From Dose 5 (Visit 6 , week 5) to Dose 8 (Visit 9, week 8) with "Take Control" CBT module: matched placebo administration, and a 15-20 minutes computer-based CBT module. Neuroimaging substudy (Visit 10, week 8): After the final medication and CBT module, participants complete final neuroimaging timepoint (T1). End-of-treatment (Visit 11, week 9 \& Visit 12, week 12): One and four weeks after the last dose and neuroimaging, participants will complete psychophysiology assessments using the same tasks as baseline.

    Behavioral: Take Control CBT Module · Other: Placebo

Interventions

  • Subcutaneous injection once weekly for 8 weeks: 2.5 mg/week initially for Weeks 1-4, then 5.0 mg/week for Weeks 5-8 (Dose escalation from 2.5 mg to 5.0 mg will occur at Week 5 unless the study physician advises continuation at the lower dose due to tolerability concerns. Delays or dose adjustments will be made per the physician's clinical judgment).

    Also known as: GLP-1/GIP receptor dual agonist

  • BehavioralTake Control CBT Module

    The Take Control intervention is a structured CBT intervention or manualised digital therapy designed to support alcohol reduction. Take Control will be completed using a computer interface with headphones in a private room. Participants will complete one module per week during treatment Weeks 1 to 8. Each module is approximately 30-45 minutes in length and will be completed independently by the participant under the supervision of a research assistant. Program content is fixed and self-paced, eliminating the need for fidelity monitoring of therapist behaviour. Take Control is an evidence-informed cognitive-behavioural intervention originally developed for use in pharmacotherapy trials for AUD and has demonstrated feasibility and acceptability in similar populations. The intervention content draws on established CBT strategies for alcohol reduction, including motivational enhancement, managing triggers, coping skills, and relapse prevention.

    Also known as: Take Control Cognitive Behavioural Therapy Module

  • OtherPlacebo

    Participants in the placebo condition will receive visually-matched sham injections, where by the placebo container and contents will be identical in appearance to Tirzepatide, except without the active ingrediant.

06

What researchers measure

Primary outcomes

  1. Heavy Drinking Days

    Reduction in Heavy Drinking Days (HDD; defined as 4 or more drinks in a day for women and 5 or more drinks in a day for men). This will be measured by the Timeline Follow Back.

    Time frame: 12 weeks (measured at baseline, during the final 4 weeks of treatment [weeks 5 - 8], end of treatment [week 9], and follow-up [week 12]).

Secondary outcomes

  1. Number of drinks per drinking day consumed

    Measured by Timeline Follow Back and corroborated with Phosphatidylethanol (PEth) levels

    Time frame: 12 weeks (weekly, from baseline visit to final follow-up visit at week 12)

  2. Abstinent days

    Measured by Timeline Follow Back

    Time frame: 12 weeks (weekly, from baseline visit to final follow-up visit at week 12)

  3. Alcohol Craving

    As measured the Visual Analogue Scale (VAS) weekly and also at pre-, during-, and post- psychophysiological cue-reactivity task completion. Scored from to 0 to 100, where higher scores indicate more severe craving.

    Time frame: 12 weeks (weekly, from baseline visit to final follow-up visit at week 12)

  4. WHO drinking risk level scale.

    The WHO drinking risk level scale categorizes alcohol consumption based on average daily intake of pure alcohol (in grams) and its associated health risk. There are 5 levels that differ based on gender: * For men, very high risk \>100 grams/day or; high risk as \>60 to 100 grams/day ; moderate risk as \>40 to 60 grams/day; and low risk as 1 to 40 grams/day. * For women, very high risk was defined as \>60 grams/day; high risk as \>40 to 60 grams/day; moderate risk as \>20 to 40 grams/day ; and low risk as 1 to 20 grams/day.

    Time frame: 12 weeks (weekly, from baseline visit to final follow-up visit at week 12)

  5. Proportion of participants with zero heavy drinking days

    Proportion of participants with zero heavy drinking days measured by the TLFB.

    Time frame: 4 weeks (weeks 5 to 8)

  6. Body weight

    Changes in body weight in kilograms (kg) from baseline to week 9 (end of treatment).

    Time frame: Measured at baseline [week 0] and at end of treatment [week 9].

  7. Waist circumference

    Changes in waist circumference in centimetres (cm) from baseline to week 9 (end of treatment).

    Time frame: Measured at baseline [week 0] and at end of treatment [week 9]

  8. Blood pressure

    Systolic and diastolic blood pressure measured weekly from baseline to end of treatment (week 8).

    Time frame: 9 weeks (weekly, from baseline visit to final dose at week 8)

  9. HbA1c

    Clinical metabolic monitoring for cardiometabolic risk and drug safety. Measures glycated haemoglobin in a blood in percentages (%). Collected at screening (Week 0) and again at the end-of-treatment visit (Week 9). Additional testing may be conducted at follow up (week 12) if clinically indicated.

    Time frame: 3 weeks (Measured at baseline [week 0] and at end of treatment [week 9], and week 12 if clinically indicated)

  10. 10-year ASCVD risk score

    A cardiometabolic biomarker providing an estimation of 10-year atherosclerotic cardiovascular disease (ASCVD) risk score, based on pooled cohort equations. This is a composite risk score derived from traditional cardiovascular risk factors, including gender, age, race, total cholesterol, total HDL cholesterol, systolic BP, previous receipt of treatment for high blood pressure (if SBP \> 120 mmHg), diabetes and smoking status. This is used to provide a risk score of atherosclerotic cardiovascular disease.

    Time frame: Measured at baseline [week 0] and end of treatment [week 9].

  11. Frequency and severity of side effects/adverse events (AEs)

    Safety outcomes including adverse events (AEs), serious adverse events (SAEs), and vital sign abnormalities, will be summarised descriptively across the study period. Feasibility outcomes (e.g., recruitment and retention rates, session attendance) will be analysed using proportions with corresponding 95% confidence intervals.

    Time frame: 12 weeks (at each visit)

  12. Number of treatment-related discontinuation

    As a measure of safety, the number of treatment-related discontinuations will be measured.

    Time frame: 12 weeks (at each visit)

  13. Total cholesterol

    Clinical metabolic monitoring for total cholesterol in millimoles per litre (mmol/L). Collected at screening (Week 0) and again at the end-of-treatment visit (Week 9). Additional testing may be conducted at follow up (week 12) if clinically indicated.

    Time frame: 3 weeks (Measured at baseline [week 0] and at end of treatment [week 9], and week 12 if clinically indicated)

  14. Triglycerides

    Clinical metabolic monitoring for triglycerides in blood sample, measured via millimoles per litre (mmol/L) as a measure of cardiometabolic risk and drug safety. Collected at screening (Week 0) and again at the end-of-treatment visit (Week 9). Additional testing may be conducted at follow up (week 12) if clinically indicated.

    Time frame: 3 weeks (Measured at baseline [week 0] and at end of treatment [week 9], and week 12 if clinically indicated)

  15. Changes in Positive and Negative Mood States

    Mood states before/after ketamine sessions assessed by PANAS (Positive and Negative Affect Schedule). This will be measured during neuroimaging and psychophysiology sessions. Used to measure an individual's emotional state, assessing two dimensions: Positive Affect (PA; captures feelings like enthusiasm and alertness), and Negative Affect (NA; measures distress and negative emotions like anger and anxiety).

    Time frame: Week 1 (prior to dose 1) and at EOT (end of treatment/week 8)

  16. Alcohol craving measure 2

    As measured by the Penn Alcohol Craving Scale (PACS). 5-item self-report questionnaire that evaluates alcohol craving over the past week. Measures frequency, intensity, duration of craving, perceived control over drinking, and overall craving severity. Each item is rated on a 7-point Likert scale (0-6). Total scores range from 0 to 30, with higher scores indicating greater craving.

    Time frame: 12 weeks - measured weekly from baseline (week 1) to outcomes/discharge (week 12)

Other outcomes

  1. Changes in cigarette use

    Measured according to the average number of cigarettes smoked per day, only among participants who reported regular smoking at baseline. Analysed with a mixed-effects models.

    Time frame: At baseline (week 0) and at end-of-treatment visit (week 9).

  2. Changes in cannabis use

    Measured according to the average number of days of cannabis used per week, only among participants who reported baseline use. Analysed with a mixed-effects models.

    Time frame: At baseline (week 0) and at end-of-treatment visit (week 9).

  3. Changes in phosphatidylethanol (PEth), an objective biomarker of alcohol use

    Changes in PEth (phosphatidylethanol) from baseline to Week 9 will be analysed using MMRM, with baseline PEth as a covariate. Collected at week 0, 9 (end-of-treatment) and optionally at week 12.

    Time frame: Baseline (Week 0), End-of-treatment (week 9) and optionally at week 12

  4. Changes in depressive symptom severity

    Measured by cumulative scores on the Center for Epidemiologic Studies Depression Scale (CES-D). This scale consists of 20 items with a minimum score of 0 and a maximum score of 60. A higher score indicates greater depressive symptomatology. Items are rated according to how often the feeling or behavior occurred in the past week (e.g. 0 = Rarely or none of the time (less than 1 day; 1 = Some or a little of the time (1-2 days); 2 = Occasionally or a moderate amount of the time (3-4 days) and 3 = Most or all of the time (5-7 days))

    Time frame: At baseline (week 0) and at end-of-treatment visit (week 9).

  5. Change in sleep disturbance and sleep problems

    As measured by cumulative scores Insomnia Severity Index (ISI). This scale consists of 7 items with a minimum total score of 0 and a maximum score of 28. A higher score indicates greater insomnia severity. Items are rated on a 0-4 scale based on the severity or impact of sleep difficulties over the past two weeks (e.g., 0 = No problem; 1 = Mild; 2 = Moderate; 3 = Severe; 4 = Very severe). A total score of 0-7 indicates "no clinically significant insomnia," 8-14 means "sub-threshold insomnia," 15-21 is "clinical insomnia (moderate severity)," and 22-28 means "clinical insomnia (severe)."

    Time frame: At baseline (week 0) and at end-of-treatment visit (week 9).

  6. Change in health-related quality of life

    As measured by cumulative scores on the 36-Item Short Form Health Survey (SF-36). Consists of 36 items grouped into 8 domains of health: 1. Physical Functioning (10 items) 2. Role Limitations due to Physical Health (4 items) 3. Role Limitations due to Emotional Problems (3 items) 4. Energy/Fatigue (4 items) 5. Emotional Well-being (5 items) 6. Social Functioning (2 items) 7. Pain (2 items) 8. General Health (5 items) Each item is scored from 0 to 100, with higher scores indicating better health status. Items are rated based on experiences over the past 4 weeks using Likert-type response options (e.g., ranging from "All of the time" to "None of the time" or "Excellent" to "Poor"). Items within a domain are summed and averaged, then transformed to a 0-100 scale. Refer to the following reference for specific transformations needed for each item: https://www.rand.org/health/surveys/mos/36-item-short-form/scoring.html

    Time frame: At baseline (week 0) and at end-of-treatment visit (week 9).

  7. Daily fluctuations in alcohol use, craving, and mood

    Measured through the use of Ecological Momentary Assessment (SEMA) via smartphone prompts.

    Time frame: Daily throughout the 12 weeks using the SEMA application

  8. Evaluation of treatment acceptability

    Collected via structured post-treatment feedback at Week 9 and optional qualitative interviews at Week 12.

    Time frame: Week 9 and optional Week 12

  9. Alcohol urge

    To assess short term alcohol urge, the Alcohol Urge Questionnaire (AUQ) will be used. This is a brief 8-item self-report questionnaire that evaluates acute alcohol craving as a single factor (unidimensional). Each item is rated on a Likert scale of 7 points, with higher scores indicating stronger urges to consume alcohol. Two of the questions are reversed scored.

    Time frame: Week 0 and Week 9 (before and after the Psychophysiological cue-reactivity tasks [if agreed to by the participant])

  10. Changes in anxiety symptom severity

    Measured by cumulative scores on the GAD-7 (Generalised Anxiety Disorder 7-item scale). Measures anxiety symptom severity over the last two weeks, and the extent to which the participant is bothered by these symptoms. Each item is scored from 0 to 3 (where 0 = not at all, 1= several days, 2= more than half of days, 3=nearly every day). This scale has a minimum score of 0 and a maximum score of 21. A higher score indicates greater severity of generalized anxiety symptoms (The total score indicates anxiety severity: 0-4 is minimal anxiety, 5-9 is mild, 10-14 is moderate, and 15-21 is severe).

    Time frame: At baseline (week 0) and at end-of-treatment visit (week 9).

  11. Changes in suicidal ideation using the Columbia Suicide Severity Rating Scale (C-SSRS).

    The C-SSRS is a structured clinician-administered instrument with strong predictive validity for suicidal behavior, used in clinical and research settings to assess the presence, severity, and intensity of suicidal ideation and behavior. The C-SSRS is administered by trained clinicians. C-SSRS scoring includes four subscales: ideation severity (items 1-5, scored by the most severe type endorsed); intensity of ideation (sum of five items including frequency, duration, controllability, deterrents, and reasons for ideation; range 2-25; higher number indicates more intense ideation); suicidal behavior (presence or absence of actual, interrupted, aborted, or preparatory behavior recorded separately); and potential lethality (medical damage rated 0-5, potential lethality rated 0-2). At baseline, this is measured by the baseline version. Higher scores indicate more severe suicidality.

    Time frame: 12 weeks (measured weekly)

  12. Withdrawal Status

    To determine changes in the severity of alcohol withdrawal symptoms the Revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar) will be used. This 10-item scale evaluates common withdrawal symptoms including nausea/vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache and orientation. Each item is rated on a scale from 0 to 7 (except orientation, which is rated 0-4), with a total score ranging from 0 to 67. Higher scores indicate more severe withdrawal symptoms.

    Time frame: Prior to neuroimaging at baseline [week 0] and the final imaging date [between week 7 and 9].

  13. Depression severity

    As measured by the Patient Health Questionnaire-9 (PHQ-9). A 9-item self-report instrument that assesses the severity of depressive symptoms over the past two weeks. Items correspond to DSM-5 criteria for major depressive disorder, including mood, interest, sleep, energy, appetite, self-worth, concentration, psychomotor changes, and suicidal thoughts. Each item is rated on a 4-point Likert scale (0 = "Not at all" to 3 = "Nearly every day"). Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity.

    Time frame: Measured weekly from baseline (week 1) to outcomes/discharge (week 12)

  14. Changes in withdrawal status (#2)

    As measured by the Short Alcohol Withdrawal Scale (SAWS). A self-report questionnaire designed to assess the severity of alcohol withdrawal symptoms over the past 24 hours. It consists of 10 items covering common withdrawal symptoms such as anxiety, tremor, sweating, nausea, sleep disturbance, and sensory sensitivity. Each item is rated on a 4-point Likert scale (0 = "Not at all" to 3 = "Severe"). Total scores range from 0 to 30, with higher scores indicating greater withdrawal severity.

    Time frame: Measured weekly from baseline (week 1) to final follow up visit (week 12)

  15. To determine risk of severe alcohol withdrawal

    As measured by the Prediction of Alcohol Withdrawal Severity Scale (PAWSS). A clinician-administered screening tool designed to predict the risk of developing severe alcohol withdrawal complications (e.g., seizures, delirium tremens) in patients. Consists of 10 items which assess recent alcohol use, history of withdrawal complications, and clinical risk factors (e.g., elevated blood alcohol level, concurrent use of sedatives). Each item is scored as 0 (absent) or 1 (present). Total scores range from 0 to 10, with higher scores indicating greater risk. A score of ≥4 suggests high risk for severe withdrawal.

    Time frame: Measured at screening (first visit) to determine withdrawal severity status

  16. Alcohol use severity

    As measured by the Alcohol Use Disorders Identification Test (AUDIT). A 10-item screening questionnaire used to identify hazardous and harmful alcohol consumption, as well as possible alcohol dependence. Items cover three domains: 1. Alcohol consumption (frequency, quantity, binge drinking) 2. Alcohol-related problems (injury, guilt, concern from others) 3. Dependence symptoms (impaired control, morning drinking) Each item is scored from 0 to 4, giving a total score range of 0-40, with higher scores indicating greater risk. Common interpretation thresholds: 0-7: Low risk 8-12: Risky drinking 13+: High risk

    Time frame: Measured at baseline

  17. Nicotine dependence

    As measured by the Fagerström Test of Nicotine Dependence (FTND). A 6-item self-report questionnaire which assess the intensity of physical addiction to nicotine. Items evaluate behaviors such as time to first cigarette after waking, daily cigarette consumption, difficulty refraining from smoking in forbidden places, and smoking patterns during the day. Each item is scored on a scale (0-1 or 0-3 depending on the question), with a total score range of 0-10, where higher scores indicate greater nicotine dependence. Common interpretation thresholds: 0-2: Very low dependence 3-4: Low dependence 5: Medium dependence 6-7: High dependence 8-10: Very high dependence

    Time frame: Measured at baseline

  18. Impulsive traits

    As measured by the UPPS Impulsive Behavior Scale. This is a self-report questionnaire designed to assess multidimensional impulsivity across five distinct facets: 1. Negative Urgency (acting rashly under distress) 2. Positive Urgency (acting rashly under extreme positive emotions) 3. Lack of Premeditation (difficulty thinking before acting) 4. Lack of Perseverance (difficulty staying focused on tasks) 5. Sensation Seeking (tendency to seek excitement and novel experiences) This version contains 59 items. Responses are rated on a Likert scale (typically 1 = "Strongly agree" to 4 = "Strongly disagree"). Scores are calculated for each facet, with higher scores indicating greater impulsivity in that domain.

    Time frame: Measured at baseline

  19. Difficulty controlling alcohol consumption

    As measured by the Impaired Control Scale (ICS). A self-report questionnaire which assesses difficulty in controlling alcohol consumption. It includes items evaluating perceived inability to stop drinking once started, failure to adhere to drinking limits, and loss of control over drinking behavior. Responses are typically rated on a Likert scale, with higher scores indicating greater impaired control.

    Time frame: Measured at baseline (week 1), dosing visit 5 (mid-point of medication schedule) and at the first (safety outcome, week 9) and second follow-up visits (outcomes/discharge, week 12)

  20. Measure of positive reinforcement from the environment

    As measured by the Environmental Reward Observation Scale (EROS). A self-report measure assessing the degree to which individuals experience positive reinforcement from their environment, and evaluates engagement in rewarding activities and perceived availability of environmental rewards. Items are rated on a Likert scale, with higher scores indicating greater environmental reinforcement.

    Time frame: Measured at baseline (week 1), dosing visit 5 (mid-point of medication schedule) and at the first (safety outcome, week 9) and second follow-up visits (outcomes/discharge, week 12)

  21. Drinking frequency in high-risk situations

    As measured by a multi-item questionnaire titled Inventory of Drinking Situation scale. This scale assesses high-risk situations for drinking, such as coping with negative emotions, social pressure, and positive mood states. Responses indicate frequency or likelihood of drinking in these contexts. Higher scores suggest greater vulnerability to relapse.

    Time frame: Measured at baseline (week 1), dosing visit 5 (mid-point of medication schedule) and at the first (safety outcome, week 9) and second follow-up visits (outcomes/discharge, week 12)

  22. Reward driven eating tendencies

    As measured by the Reward-Based Eating Drive Scale (R-BEDS). A self-report tool assessing compulsive eating behaviors driven by reward sensitivity. It evaluates loss of control over eating, lack of satiety, and preoccupation with food. It consists of 9 items, each rated on a Likert scale from 1 to 5: * 1 = Strongly Disagree * 5 = Strongly Agree Items are grouped into three subscales: 1. Loss of Control Over Eating 2. Lack of Satiety 3. Preoccupation With Food Total Scores range from 9 to 45, where higher scores indicate greater reward-driven eating tendencies.

    Time frame: Measured weekly from baseline (week 1) to final follow up visit (week 12)

  23. Presence and severity of food addiction symptoms

    As measured by the Yale Food Addiction Scale (YFAS). Assesses addictive-like eating behaviors based on DSM criteria for substance use disorders. It measures symptoms such as tolerance, withdrawal, loss of control, and continued use despite negative consequences. Scoring identifies 1) symptom count ranging from 0 to 7 reflecting number of addiction like criteria endorsed with higher scores indicating greater food addiction severity; and 2) a dichotomous "diagnosis" that indicates whether a threshold of 3/\< "symptoms" plus clinically significant impairment or distress is satisfied.

    Time frame: Measured at baseline

  24. Trait level food craving tendencies

    Measured by the General Food Craving Questionnaire - Trait (G-FCQ-T). This is a self-report measure that assesses the general tendency to experience food cravings over time. It includes multiple subscales. Items are rated on a Likert scale, with higher scores indicating stronger trait-level food cravings. There are 21 items scored on a Likert scale ranging from 1 = never to 6 = always, with a score range between 21 and 126. Higher scores are indicative of more frequent and intense trait food cravings.

    Time frame: Measured at baseline and at follow-up 1 (safety outcomes, week 9)

  25. Anhedonia (ability to experience pleasure in last few days)

    As measured by the Snaith-Hamilton Pleasure Scale (SHPS). A self-report questionnaire which assesses anhedonia across domains such as social interactions, food and drink, sensory experiences, and hobbies. Items are rated on a Likert scale, with the final score ranging from 14 to 56. Higher scores indicate greater anhedonia. Each item has four possible responses: strongly disagree, disagree, agree, or strongly agree.

    Time frame: Measured at baseline (week 1), dosing visit 5 (mid-point of medication schedule) and at the first (safety outcome, week 9) and second follow-up visits (outcomes/discharge, week 12)

  26. Self-efficacy for maintaining abstinence

    As measured by the Alcohol Abstinence Self-Efficacy Scale (AASE). Self report measure assessing confidence in resisting alcohol use across high-risk situations (e.g., negative emotions, social pressure). Items are rated on a Likert scale, with higher scores indicating greater self-efficacy for maintaining abstinence. Each item is scored on a scale from 1 (not at all confident) to 5 (extremely confident) relating to the level of confidence a participant has to not drink alcohol.

    Time frame: Measured at baseline (week 1), dosing visit 5 (mid-point of medication schedule) and at the first (safety outcome, week 9) and second follow-up visits (outcomes/discharge, week 12)

  27. Compulsions and obsessive thoughts related to alcohol use

    As measured by the Obsessive-Compulsive Drinking Scale (OCDS). A 14-item questionnaire that measures an individual's severity of obsessive thoughts and compulsions to use alcohol. Includes two subscales 1. obsessions (thoughts, urges) and 2. compulsions (drinking behaviors). Higher scores indicate greater cognitive and behavioral preoccupation with alcohol. Each item is scored on a scale of 0 to 4.

    Time frame: Measured at baseline (week 1), dosing visit 5 (mid-point of medication schedule) and at the first (safety outcome, week 9) and second follow-up visits (outcomes/discharge, week 12)

  28. Food cravings at a specific point in time

    As measured by the General Food Craving Questionnaire-State (G-FCQ-S). A self-report measure assessing momentary food cravings at a specific point in time. Items capture craving intensity, desire, and preoccupation. Higher scores indicate stronger state-level cravings.

    Time frame: Measured weekly from baseline (week 1) to final follow up visit (week 12)

  29. Intensity of cigarette craving

    As measured by the Tiffany Questionnaire of Smoking Urges (QSU). Measures the intensity and nature of cigarette craving, assessing 2 dimensions: 1. Desire and intention to smoke for positive reinforcement (e.g., pleasure, satisfaction) and.... 2. Urgency to smoke to relieve negative affect or withdrawal symptoms There are 32 items, each rated on a 7-point Likert scale ranging from 1= strongly disagree to 7 = strongly agree. Higher total summed scores are indicative of a stronger craving and motivation to smoke.

    Time frame: Measured weekly from baseline (week 1) to final follow up visit (week 12)

  30. Motivation and demand for alcohol.

    As measured by the Alcohol Purchase Task (APT). Measure assesses demand and motivation for alcohol under varying price conditions. Participants indicate how many drinks they would purchase at different prices. Outcomes include indices such as intensity, elasticity, and breakpoint, reflecting motivation and valuation of alcohol.

    Time frame: Measured weekly from baseline (week 1) to final follow up visit (week 12)

07

Study locations

1 site
  • Drug Health Services, Royal Prince Alfred Hospital
    Sydney, New South Wales 2050, Australia
    • Kirsten C Morley, PhD · ContactKirsten.morley@sydney.edu.au
    • Central Contact Line · Contact0459877108
    • Paul Haber, MD, RACP, FAChAM · Principal investigator
    • Kirsten Morley, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for May 2027, 16 months later.

Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 16 months is below that.

Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 18, 2025
StartEst.
Jan 15, 2026
Primary completionEst.
May 15, 2027
CompletionEst.
Jan 15, 2028
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07292519
Lead sponsor
South West Sydney Local Health District
Collaborators
University of Sydney
Responsible party
Kirsten Morley BPsych MPH PhD (Professor, South West Sydney Local Health District) — Principal investigator
First posted
Dec 18, 2025
Start date
Jan 15, 2026 (estimated)
Primary completion
May 15, 2027 (estimated)
Completion
Jan 15, 2028 (estimated)
Last update
Dec 18, 2025

Study contacts

Kirsten C Morley, PhD
Contact
Kirsten.morley@sydney.edu.au
+61295153636
Paul Haber, MD, RACP, FAChAM
principal investigator · Sydney Local Health District

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion